Immunotherapies for Alzheimer’s Disease—A Review
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that falls under the umbrella of dementia and is characterised by the presence of highly neurotoxic amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) of tau protein within the brain. Historically, treatments for AD have cons...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/9/1527 |
| _version_ | 1797481581833617408 |
|---|---|
| author | Zachary Valiukas Ramya Ephraim Kathy Tangalakis Majid Davidson Vasso Apostolopoulos Jack Feehan |
| author_facet | Zachary Valiukas Ramya Ephraim Kathy Tangalakis Majid Davidson Vasso Apostolopoulos Jack Feehan |
| author_sort | Zachary Valiukas |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that falls under the umbrella of dementia and is characterised by the presence of highly neurotoxic amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) of tau protein within the brain. Historically, treatments for AD have consisted of medications that can slow the progression of symptoms but not halt or reverse them. The shortcomings of conventional drugs have led to a growing need for novel, effective approaches to the treatment of AD. In recent years, immunotherapies have been at the forefront of these efforts. Briefly, immunotherapies utilise the immune system of the patient to treat a condition, with common immunotherapies for AD consisting of the use of monoclonal antibodies or vaccines. Most of these treatments target the production and deposition of Aβ due to its neurotoxicity, but treatments specifically targeting tau protein are being researched as well. These treatments have had great variance in their efficacy and safety, leading to a constant need for the research and development of new safe and effective treatments. |
| first_indexed | 2024-03-09T22:16:40Z |
| format | Article |
| id | doaj.art-d2abb304eeeb4ff8a21ea2637accdfac |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T22:16:40Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-d2abb304eeeb4ff8a21ea2637accdfac2023-11-23T19:22:39ZengMDPI AGVaccines2076-393X2022-09-01109152710.3390/vaccines10091527Immunotherapies for Alzheimer’s Disease—A ReviewZachary Valiukas0Ramya Ephraim1Kathy Tangalakis2Majid Davidson3Vasso Apostolopoulos4Jack Feehan5College of Health and Biomedicine, Victoria University, Melbourne, VIC 3011, AustraliaInstitute for Health and Sport, Victoria University, Melbourne, VIC 3021, AustraliaFirst Year College, Victoria University, Melbourne, VIC 3011, AustraliaInstitute for Health and Sport, Victoria University, Melbourne, VIC 3021, AustraliaInstitute for Health and Sport, Victoria University, Melbourne, VIC 3021, AustraliaInstitute for Health and Sport, Victoria University, Melbourne, VIC 3021, AustraliaAlzheimer’s disease (AD) is a chronic neurodegenerative disorder that falls under the umbrella of dementia and is characterised by the presence of highly neurotoxic amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) of tau protein within the brain. Historically, treatments for AD have consisted of medications that can slow the progression of symptoms but not halt or reverse them. The shortcomings of conventional drugs have led to a growing need for novel, effective approaches to the treatment of AD. In recent years, immunotherapies have been at the forefront of these efforts. Briefly, immunotherapies utilise the immune system of the patient to treat a condition, with common immunotherapies for AD consisting of the use of monoclonal antibodies or vaccines. Most of these treatments target the production and deposition of Aβ due to its neurotoxicity, but treatments specifically targeting tau protein are being researched as well. These treatments have had great variance in their efficacy and safety, leading to a constant need for the research and development of new safe and effective treatments.https://www.mdpi.com/2076-393X/10/9/1527Alzheimer’s diseaseimmunotherapiesvaccinesamyloid-betadementia |
| spellingShingle | Zachary Valiukas Ramya Ephraim Kathy Tangalakis Majid Davidson Vasso Apostolopoulos Jack Feehan Immunotherapies for Alzheimer’s Disease—A Review Vaccines Alzheimer’s disease immunotherapies vaccines amyloid-beta dementia |
| title | Immunotherapies for Alzheimer’s Disease—A Review |
| title_full | Immunotherapies for Alzheimer’s Disease—A Review |
| title_fullStr | Immunotherapies for Alzheimer’s Disease—A Review |
| title_full_unstemmed | Immunotherapies for Alzheimer’s Disease—A Review |
| title_short | Immunotherapies for Alzheimer’s Disease—A Review |
| title_sort | immunotherapies for alzheimer s disease a review |
| topic | Alzheimer’s disease immunotherapies vaccines amyloid-beta dementia |
| url | https://www.mdpi.com/2076-393X/10/9/1527 |
| work_keys_str_mv | AT zacharyvaliukas immunotherapiesforalzheimersdiseaseareview AT ramyaephraim immunotherapiesforalzheimersdiseaseareview AT kathytangalakis immunotherapiesforalzheimersdiseaseareview AT majiddavidson immunotherapiesforalzheimersdiseaseareview AT vassoapostolopoulos immunotherapiesforalzheimersdiseaseareview AT jackfeehan immunotherapiesforalzheimersdiseaseareview |